NEW YORK (GenomeWeb News) – German biopharmaceutical firm Probiodrug and the VU University Medical Center Alzheimer Center in The Netherlands today announced a collaboration to evaluate molecular biomarker assays for Alzheimer's disease.

The assays will be assessed for their diagnostic, pharmacodynamic, and therapeutic use. Cerebrospinal fluid samples from well-characterized Alzheimer's disease patients at different stages of the illness will be analyzed and compared with CSF from age-matched control samples as part of the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.